cd47 siRNA lipid nanoparticles

CD47 siRNA lipid nanoparticles (CD47 siLNP) are an experimental RNA interference therapeutic designed to silence the expression of CD47, a cell-surface protein that acts as an anti-phagocytic don't eat me signal. Developed by researchers at Boston Children's Hospital, Harvard Medical School, and Stanford University, this formulation uses lipid nanoparticles (LNPs) to deliver small interfering RNA (siRNA) specifically to endothelial cells. In preclinical models of atherosclerosis, the drug has been shown to restore PPARγ-mediated cholesterol efflux and efferocytosis, which are typically impaired by CD47 upregulation in human and murine plaques. By targeting the endothelium specifically, this approach aims to reduce vascular inflammation and plaque progression while avoiding the transient anemia often caused by systemic CD47-blocking antibodies.

Other names

lipid nanoparticle-encapsulated siRNAs targeting endothelial CD47endothelial targeting CD47 silencing siLNPs